
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana demonstrates a positive outlook due to stable cost trends observed from the third to fourth quarter of 2024, with anticipated improvements in adjusted EPS driven by potential advancements in star ratings for Medicare contracts. The company is positioned for growth through ongoing investments aimed at enhancing clinical excellence and achieving margins in group Medicare Advantage, with a solid competitive standing supported by its above-industry star rating profile. Additionally, management’s focused efforts on Stars recovery initiatives, coupled with strategic investments in pricing and operational improvements, point toward long-term sustainable growth for the company.
Bears say
Humana's outlook appears negative primarily due to a missed opportunity in achieving its Star ratings, which has led to heightened margin pressure and concerns over medical loss ratio (MLR) stability. Projections indicate that the timeline for reaching target Medicare Advantage (MA) margins has shifted from 2027 to 2028, creating further uncertainty surrounding the company’s future profitability. Additionally, ongoing elevated investments aimed at enhancing clinical excellence are expected to persist beyond 2025, suggesting that the financial improvements may take longer than previously anticipated.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares